Latest Advances in Vebreltinib for High-Grade Glioma: Further Validation of Its Therapeutic Value

High-grade glioma (HGG) is one of the most aggressive malignant tumors of the central nervous system. Despite continuous advances in surgery, radiotherapy, and chemotherapy, patients still face major challenges, including high recurrence rates, poor prognosis, and limited survival outcomes.

In recent years, advances in molecular classification have opened new opportunities for targeted therapies in selected patient populations.

As a highly selective MET inhibitor independently developed in China, Vebreltinib (APL-101) has been approved for the treatment of PTPRZ1-MET (ZM) fusion-positive glioma. Recent clinical research has further validated its therapeutic value in improving overall survival (OS) among patients with high-grade glioma.

As a pharmaceutical information platform dedicated to innovative medicines and precision oncology, DengYueMed reviews the latest research progress and clinical significance of Vebreltinib in high-grade glioma treatment.

---

What Is High-Grade Glioma?

High-grade glioma refers to highly malignant primary brain tumors classified by the World Health Organization (WHO).

The major types include:

• Glioblastoma (GBM)
• IDH-mutant Grade 4 Astrocytoma

These tumors are characterized by aggressive growth, diffuse infiltration, and a high likelihood of recurrence.

Despite multimodal treatment—including surgical resection, radiotherapy, and temozolomide chemotherapy—many patients eventually experience disease progression.

Consequently, identifying novel molecular targets has become an important direction in neuro-oncology research.

---

Vebreltinib (APL-101) is the world’s first approved MET inhibitor for patients with PTPRZ1-MET (ZM) fusion-positive glioma.

---

What Is Vebreltinib?

Vebreltinib (development code APL-101) is a National Class 1 innovative drug developed by Avistone Biotechnology.

It is a highly selective oral MET receptor tyrosine kinase inhibitor (MET-TKI).

Its major characteristics include:

• Highly selective inhibition of the MET signaling pathway
• Excellent blood-brain barrier penetration
• Favorable drug exposure in intracranial lesions
• Precise targeting of MET-driven tumors

Vebreltinib has become the first MET-targeted therapy approved globally for PTPRZ1-MET (ZM) fusion-positive glioma, representing a major milestone in precision neuro-oncology.

---

Why Is MET-Targeted Therapy Important?

Gliomas are genetically heterogeneous.

Among various molecular alterations, PTPRZ1-MET (ZM) fusion continuously activates the MET signaling pathway, promoting:

• Tumor proliferation
• Cell migration
• Invasion
• Disease progression

Vebreltinib selectively inhibits MET kinase activity and suppresses downstream signaling pathways including:

• MAPK
• PI3K/AKT

By blocking these pathways, Vebreltinib inhibits tumor growth and offers a more precise treatment strategy.

Not all patients are suitable candidates for MET-targeted therapy. Molecular testing, including next-generation sequencing (NGS), is recommended to confirm MET alterations before treatment.

---

Latest Clinical Research Further Validates Therapeutic Value

A multicenter Phase III clinical study published in March 2026 further evaluated the efficacy and safety of Vebreltinib in patients with previously treated PTPRZ1-MET fusion-positive high-grade glioma.

The trial enrolled 81 patients across 28 neurosurgical centers throughout China, making it one of the largest randomized studies conducted in this molecular subtype.

---

Main Clinical Results

Compared with conventional treatment, Vebreltinib demonstrated encouraging improvements across multiple efficacy endpoints.

Endpoint	Vebreltinib	Control
Median Overall Survival (OS)	6.3 months	3.4 months
Median Progression-Free Survival (PFS)	1.9 months	1.1 months
Objective Response Rate (ORR)	9.5%	2.6%

The results demonstrated significant improvement in overall survival together with better disease control.

---

Which Patients Benefited Most?

Subgroup analyses suggested greater treatment benefit among:

• Patients with IDH-mutant high-grade glioma
• Patients whose baseline tumor diameter was ≤3 cm
• Patients achieving prolonged disease stabilization

These findings further highlight the importance of precision molecular diagnosis when selecting targeted therapies.

---

Safety Profile

Safety remains an important consideration for recurrent brain tumors.

The Phase III study showed:

• A manageable overall safety profile
• Grade ≥3 treatment-related adverse events comparable to the control group
• No unexpected safety signals
• No treatment-related deaths

Overall, Vebreltinib improved survival without substantially increasing severe toxicity.

---

Which Patients May Be Eligible?

Current evidence suggests Vebreltinib may be considered for patients who meet the following criteria:

• Pathologically confirmed high-grade glioma
• PTPRZ1-MET (ZM) fusion or other MET abnormalities confirmed through molecular testing
• Disease recurrence or progression after standard therapy
• Eligibility determined through multidisciplinary evaluation

Because molecular characteristics differ among patients, treatment decisions should always be individualized.

---

Future Perspectives

Precision medicine continues transforming the treatment landscape of glioma.

Driver gene-based therapies are allowing more patients to receive individualized treatment.

The latest Phase III study further strengthens the evidence supporting MET-targeted therapy in PTPRZ1-MET fusion-positive glioma.

Future research is expected to explore:

• Long-term survival outcomes
• Combination therapy strategies
• Earlier treatment settings
• Real-world clinical effectiveness
• Additional predictive biomarkers

These advances may further optimize patient selection and improve long-term outcomes.

---

Conclusion

High-grade glioma remains one of the most challenging diseases in neuro-oncology.

As China’s first approved MET inhibitor for PTPRZ1-MET (ZM) fusion-positive glioma, Vebreltinib has demonstrated encouraging survival benefits together with a manageable safety profile in recent clinical studies.

For patients harboring relevant molecular alterations, these findings provide additional evidence supporting precision targeted therapy and represent an important step toward more personalized treatment.

DengYueMed will continue to monitor innovative oncology therapies, targeted medicines, and precision medicine advances, providing healthcare professionals and global pharmaceutical partners with timely insights into emerging drug developments.